Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Huperzine A Controlled-Release Tablets in Mild-to-Moderate Alzheimer's Disease
NCT07066826Phase 3Recruiting
- Sponsor
- Wanbangde Pharmaceutical Holding Group
- Start
- Aug 2025
- Primary completion
- Aug 2028
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Huperzine A in Alzheimer's disease (AD) (3 arms), sponsored by Wanbangde Pharmaceutical Holding Group. Primary endpoints: Alzheimer's Disease Assessment Scale-Cognitive Subscale 11 at 24 weeks and Alzheimer's Disease Cooperative Study - Activities of Daily Living at 24 weeks. Started Aug 2025; status: recruiting.
02
Drugs
Huperzine A
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07066826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07066826.